CRISPR Therapeutics and the Future of Gene Editing in Medicine

In late 2023, Casgevy — a CRISPR/Cas9-based therapy co-developed by Vertex Pharmaceuticals and CRISPR Therapeutics — became the first gene-editing treatment approved by the FDA, targeting sickle cell disease and beta-thalassemia. The milestone has accelerated investment and interest across the gene therapy space.

Pharmaceutical giants like Pfizer, AstraZeneca, and Novartis are deepening their CRISPR portfolios through acquisitions and partnerships. Meanwhile, base editing and prime editing technologies promise even more precise corrections with fewer off-target effects. The pipeline for rare genetic diseases, certain cancers, and inherited blindness conditions is expanding rapidly, with analysts expecting dozens of gene therapy approvals over the next decade.